Status:
WITHDRAWN
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity
Lead Sponsor:
Eurofarma Laboratorios S.A.
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18-100 years
Brief Summary
An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with ...
Eligibility Criteria
Inclusion
- Adult patients
- Both sexes
- Diagnose of overweight with comorbidity(ies) or obesity
- Treatment use of sibutramine combined with topiramate
- Treatment prescription between 2011 and the beginning of the study
Exclusion
- Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity
- Individual use of one of the medications (sibutramine or topiramate)
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05209997
Start Date
December 1 2024
End Date
December 1 2025
Last Update
February 28 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Eurofarma Laboratórios S.A
São Paulo, São Paulo, Brazil, 06696-000
2
HC-FMUSP
São Paulo, São Paulo, Brazil